Sarepta Therapeutics (NASDAQ:SRPT) Price Target Increased to $213.00 by Analysts at Bank of America

Sarepta Therapeutics (NASDAQ:SRPTFree Report) had its target price upped by Bank of America from $166.00 to $213.00 in a research report released on Friday morning, Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

SRPT has been the topic of several other reports. Needham & Company LLC reaffirmed a buy rating and set a $166.00 price objective on shares of Sarepta Therapeutics in a report on Monday, May 20th. Oppenheimer raised shares of Sarepta Therapeutics from a market perform rating to an outperform rating and set a $180.00 price objective on the stock in a report on Tuesday, May 14th. BMO Capital Markets reaffirmed an outperform rating and set a $170.00 price objective on shares of Sarepta Therapeutics in a report on Friday, June 14th. Robert W. Baird increased their price objective on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an outperform rating in a report on Friday. Finally, Cantor Fitzgerald reaffirmed a neutral rating and set a $128.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, May 2nd. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $184.83.

View Our Latest Research Report on Sarepta Therapeutics

Sarepta Therapeutics Stock Up 1.9 %

NASDAQ:SRPT opened at $163.85 on Friday. The company’s fifty day moving average price is $126.47 and its 200-day moving average price is $120.71. Sarepta Therapeutics has a 1-year low of $55.25 and a 1-year high of $173.25. The firm has a market capitalization of $15.49 billion, a P/E ratio of 1,489.55 and a beta of 0.96. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44.

Sarepta Therapeutics (NASDAQ:SRPTGet Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.84. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The firm had revenue of $413.50 million for the quarter, compared to the consensus estimate of $375.52 million. During the same period in the prior year, the firm posted ($1.44) earnings per share. The firm’s quarterly revenue was up 63.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Sarepta Therapeutics will post 2.99 EPS for the current year.

Insider Buying and Selling

In related news, insider Dallan Murray sold 3,635 shares of the firm’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total transaction of $508,900.00. Following the completion of the sale, the insider now directly owns 18,125 shares in the company, valued at $2,537,500. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 7.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Garde Capital Inc. acquired a new stake in Sarepta Therapeutics during the first quarter worth about $140,000. Cetera Investment Advisers increased its position in shares of Sarepta Therapeutics by 27.6% during the first quarter. Cetera Investment Advisers now owns 11,991 shares of the biotechnology company’s stock valued at $1,552,000 after acquiring an additional 2,590 shares during the last quarter. Farallon Capital Management LLC increased its position in shares of Sarepta Therapeutics by 102.8% during the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after acquiring an additional 1,243,427 shares during the last quarter. New Covenant Trust Company N.A. acquired a new stake in shares of Sarepta Therapeutics during the first quarter valued at about $32,000. Finally, Comerica Bank increased its position in shares of Sarepta Therapeutics by 489.4% during the first quarter. Comerica Bank now owns 3,336 shares of the biotechnology company’s stock valued at $432,000 after acquiring an additional 2,770 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

(Get Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Featured Stories

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.